Overview

Long-Term Safety of PRC-063 in Adolescents and Adults With ADHD

Status:
Completed
Trial end date:
2015-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this six month, open-label study is to evaluate the long-term safety and efficacy of PRC-063 in adults and adolescents with ADHD.
Phase:
Phase 3
Details
Lead Sponsor:
Rhodes Pharmaceuticals, L.P.
Collaborator:
Purdue Pharma LP
Treatments:
Methylphenidate